Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease

LI Lu; QIU Rongrong; DONG Feng

doi:10.6039/j.issn.1001-0408.2026.11.13

您当前的位置：

首页 >

文章列表页 >

Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease

更新时间：2026-06-10

- Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease
- ZHONGGUO YAOFANG Vol. 37, Issue 11, Pages: 1457-1461(2026)
- 作者机构：
  
  无锡市第二人民医院（江南大学附属中心医院）心血管内科，江苏无锡　214002
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.11.13
  CLC： R969.4;R972
- Received：12 January 2026，
  
  Revised：2026-05-19，
  
  Accepted：19 May 2026，
  
  Published：15 June 2026
- 稿件说明：
移动端阅览
李录,邱荣荣,董丰.达格列净治疗左心疾病相关性肺动脉高压的疗效及预后观察 [J].中国药房,2026,37(11):1457-1461.

LI Lu,QIU Rongrong,DONG Feng.Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease[J].ZHONGGUO YAOFANG,2026,37(11):1457-1461.
李录,邱荣荣,董丰.达格列净治疗左心疾病相关性肺动脉高压的疗效及预后观察 [J].中国药房,2026,37(11):1457-1461. DOI： 10.6039/j.issn.1001-0408.2026.11.13.

LI Lu,QIU Rongrong,DONG Feng.Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease[J].ZHONGGUO YAOFANG,2026,37(11):1457-1461. DOI： 10.6039/j.issn.1001-0408.2026.11.13.

摘要

目的

评估达格列净对左心疾病相关性肺动脉高压（PH-LHD）患者临床疗效及预后的影响，为其临床应用提供依据。

方法

回顾性纳入2023年1月1日至2025年6月30日无锡市第二人民医院的PH-LHD住院患者135例，根据治疗方式不同分为对照组（74例，常规治疗）和达格列净组（61例，在对照组基础上加用达格列净）。比较两组患者治疗前和治疗12周后的血压[收缩压、舒张压、肺动脉收缩压（PASP）]、超声心动图心功能指标[心输出量、心指数、左室射血分数（LVEF）、右心射血分数（RVEF）、左心房直径、左心室壁厚度]、炎症因子[白细胞介素6（IL-6）、高敏C反应蛋白（hs-CRP）]、脑钠肽（BNP）及6分钟步行距离（6MWD），并比较两组患者随访期间全因死亡发生率及心衰加重再住院频率。

结果

治疗12周后，两组患者的收缩压、舒张压、PASP、左心房直径、IL-6、hs-CRP及BNP水平均较治疗前显著降低或缩短，心指数和6MWD均较治疗前显著升高或延长（

＜0.05）；达格列净组患者的心输出量较治疗前显著升高（

＜0.05）。达格列净组患者的收缩压、PASP、左心房直径、IL-6、hs-CRP及BNP水平均显著低于或短于对照组，心输出量、心指数及6MWD均显著高于或长于对照组（

＜0.05）；两组患者的LVEF、RVEF及左心室壁厚度比较，差异均无统计学意义（

＞0.05）。对照组和达格列净组患者的中位随访时间分别为17.9个月和17.3个月。随访期间，达格列净组患者的全因死亡发生率低于对照组，但差异无统计学意义（

＞0.05）；其心衰加重再住院频率显著低于对照组（

＜0.05）。

结论

在常规治疗基础上加用达格列净能进一步降低PH-LHD患者的肺动脉压力、炎症因子及BNP水平，改善部分心功能相关指标和运动耐量，并降低心衰加重再住院频率。

Abstract

OBJECTIVE

To evaluate the clinical efficacy of dapagliflozin in patients with pulmonary hypertension associated with left heart disease （PH-LHD） and its effect on prognosis， and to provide evidence for its clinical application.

METHODS

A total of 135 hospitalized patients with PH-LHD admitted to Wuxi No. 2 People’s Hospital from January 1， 2023 to June 30， 2025 were retrospectively included. According to the treatment regimen， the patients were divided into a control group （74 cases， receiving conventional treatment） and a dapagliflozin group （61 cases， receiving dapagliflozin in addition to conventional treatment）. Blood pressure [systolic blood pressure， diastolic blood pressure， and pulmonary artery systolic pressure （PASP）]， echocardiographic cardiac function parameters [cardiac output， cardiac index， left ventricular ejection fraction （LVEF）， right ventricular ejection fraction （RVEF）， left atrial diameter， and left ventricular wall thickness]， inflammatory factors [interleukin-6 （IL-6） and high-sensitivity C-reactive protein （hs-CRP）]， brain natriuretic peptide （BNP）， and 6-minute walking distance （6MWD） were compared between the two groups before treatment and after 12 weeks of treatment. All-cause mortality and the frequency of rehospitalization due to worsening heart failure during follow-up were also compared.

RESULTS

After 12 weeks of treatment， systolic blood pressure， diastolic blood pressure， PASP， left atrial diameter， IL-6， hs-CRP， and BNP levels were significantly decreased or shortened in both groups， while cardiac index and 6MWD were significantly increased or prolonged compared with those before treatment （

＜0.05）. Cardiac output in the dapagliflozin group was significantly increased compared with that before treatment （

＜0.05）. Systolic blood pressure， PASP， left atrial diameter， IL-6， hs-CRP， and BNP levels in the dapagliflozin group were significantly lower or shorter than those in the control group， while cardiac output， cardiac index， and 6MWD were significantly higher or longer than those in the control group （

＜0.05）. There were no statistically significant differences in LVEF， RVEF， or left ventricular wall thickness between the two groups （

＞0.05）. The median follow-up times in the control group and dapagliflozin group were 17.9 months and 17.3 months， respectively. During follow-up， all-cause mortality in the dapagliflozin group was lower than that i

n the control group， but the difference was not statistically significant （

＞0.05）； the frequency of rehospitalization due to worsening heart failure was significantly lower than that in the control group （

＜0.05）.

CONCLUSIONS

On the basis of conventional treatment， the addition of dapagliflozin can further reduce pulmonary artery pressure， inflammatory factor levels， and BNP levels in patients with PH-LHD， improve some cardiac function-related parameters and exercise tolerance， and reduce the frequency of rehospitalization due to worsening heart failure.

关键词

Keywords

references

GERGES C ， MONTANI D ， HUMBERT M ， et al . Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease：a moving target [J ] . Eur Respir J ， 2024 ， 63 （ 3 ）： 2302280 .

MADONNA R ， BIONDI F ， GHELARDONI S ， et al . Pulmonary hypertension associated to left heart disease：phenotypes and treatment [J ] . Eur J Intern Med ， 2024 ， 129 ： 1 - 15 .

ZEDER K ， BROWN C H ， SANTI Aet al . The prevalence of pulmonary hypertension associated with left heart disease：a systematic review and meta-analysis [J ] . Cardiovasc Res ， 2025 ， 121 （ 17 ）： 2632 - 2643 .

ESTRADA R A ， SAHAY S ， TONELLI A R . Treatment of pulmonary hypertension after seven world symposia [J ] . Ther Adv Respir Dis ， 2025 ， 19 ： 17534666251342898 .

PETRIE M C ， VERMA S ， DOCHERTY K F ， et al . Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes [J ] . JAMA ， 2020 ， 323 （ 14 ）： 1353 - 1368 .

JHUND P S ， KONDO T ， BUTT J H ， et al . Dapagliflozin across the range of ejection fraction in patients with heart failure：a patient-level，pooled meta-analysis of DAPA-HF and DELIVER [J ] . Nat Med ， 2022 ， 28 （ 9 ）： 1956 - 1964 .

HEIDENREICH P A ， BOZKURT B ， AGUILAR D ， et al . 2022 AHA/ACC/HFSA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines [J ] . Circulation ， 2022 ， 145 （ 18 ）： e895 - e1032 .

REDDY Y N V ， CARTER R E ， SORIMACHI H ， et al . Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction：a secondary analysis of a randomized clinical trial [J ] . JAMA Cardiol ， 2024 ， 9 （ 9 ）： 843 .

SOLOMON S D ， MCMURRAY J J V ， CLAGGETT B ， et al . Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction [J ] . N Engl J Med ， 2022 ， 387 （ 12 ）： 1089 - 1098 .

HUMBERT M ， KOVACS G ， HOEPER M M ， et al . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [J ] . Eur Respir J ， 2023 ， 61 （ 1 ）： 2200879 .

ILONZE O J ， EBONG I A ， GUGLIN M ， et al . Considerations in the diagnosis and management of pulmonary hypertension associated with left heart disease [J ] . JACC Heart Fail ， 2024 ， 12 （ 8 ）： 1328 - 1342 .

SU A Y ， CSERE M M ， SHAN R ， et al . Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes：a systematic review and network meta-analysis of randomized controlled trials [J ] . Diabetes Res Clin Pract ， 2025 ， 224 ： 112219 .

MROUEH A ， ALGARA-SUAREZ P ， et al . SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes ENOS-NO/ROS imbalance [J ] . Cardiovasc Res ， 2025 ， 121 （ 4 ）： 643 - 657 .

WANG M ， LIU X M ， DING B ， et al . SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis [J ] . Biomed Pharmacother ， 2024 ， 177 ： 116994 .

PANDEY A K ， BHATT D L ， PANDEY A ， et al . Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction [J ] . Eur Heart J ， 2023 ， 44 （ 37 ）： 3640 - 3651 .

KIRSCHBAUM K ， VASA-NICOTERA M ， ZEIHER A M ， et al . SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure：further evidence for improved hemodynamics by continuous pressure monitoring [J ] . Clin Res Cardiol ， 2022 ， 111 （ 4 ）： 469 - 472 .

ZHANG L N . Analysis of dapagliflozin combination therapy in heart failure with reduced ejection fraction and its correlation with inflammatory markers [J ] . Am J Transl Res ， 2025 ， 17 （ 9 ）： 7426 - 7437 .

ADU-AMANKWAAH J ， SHI Y ， SONG H Q ， et al . Signaling pathways and targeted therapy for pulmonary hypertension [J ] . Signal Transduct Target Ther ， 2025 ， 10 ： 207 .

GE T ， YANG Y ， ZHAO Y F . A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease [J ] . Perfusion ， 2023 ， 38 （ 8 ）： 1697 - 1704 .

McMurray J J V ， Solomon S D ， Inzucchi S E ， et al . Dapagliflozin in patients with heart failure and reduced ejection fraction [J ] . N Engl J Med ， 2019 ， 381 （ 21 ）： 1995 - 2008 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

雌激素+黄体素联合常规方案治疗女性绝经后骨质疏松症的效果观察

放弃PCI术接受药物综合治疗的冠心病合并心力衰竭患者的预后分析

地佐辛对乳腺癌患者术后疼痛及炎性因子的影响

血必净注射液对脓毒症患者凝血功能及预后的影响

参附注射液对急诊心肺复苏术后患者脏器功能的保护及改善预后的作用

Related Author

WANG Feng

LI Zhenwu

YAN Ruifeng

LI Zhian

ZHANG Yang

ZOU Xiaoyi

TAN Qiang

SUN Qiang

Related Institution

Department of Endocrinology,Chongqing Emergency Medical Center/Chongqing University Central Hospital

Department of Endocrinology,The General Hospital of Western Theater Command PLA

Nutrition Department,The General Hospital of Western Theater Command PLA

Department of Infectious Disease

Laboratory of Infection and Immunity

⁰